0001683168-25-008564.txt : 20251119 0001683168-25-008564.hdr.sgml : 20251119 20251119170007 ACCESSION NUMBER: 0001683168-25-008564 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251117 FILED AS OF DATE: 20251119 DATE AS OF CHANGE: 20251119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Climaco John M CENTRAL INDEX KEY: 0001546797 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 251500020 MAIL ADDRESS: STREET 1: PO BOX 326 CITY: PARK CITY STATE: UT ZIP: 84060 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 4 1 ownership.xml X0508 4 2025-11-17 0 0001729427 CNS Pharmaceuticals, Inc. CNSP 0001546797 Climaco John M C/O CNS PHARMACEUTICALS, INC. 100 WEST LOOP SOUTH, SUITE 900 HOUSTON TX 77027 1 1 0 0 Chief Executive Officer 0 Option to purchase common stock 30 2025-11-17 4 A 0 9761 0 A 2035-11-17 Common Stock 9761 9761 D The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025. The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date. Issued in connection with the reporting person's employment with the Company. /s/ Christopher Downs, Attorney-in-Fact 2025-11-19